
Imipenem/relebactam had the lowest mutant prevention concentrations (MPCs) among β-lactams against Pseudomonas aeruginosa, followed by ceftolozane/tazobactam. Mutant resistance mechanisms varied: ceftazidime/avibactam and ceftolozane/tazobactam selected ampC and galU mutations, while cefiderocol mutants exhibited iron-uptake defects. Carbapenems targeted oprD first. Findings highlight resistance patterns in extensively drug-resistant strains, aiding β-lactam treatment strategies for XDR P. aeruginosa infections.
Like
Save
Share